DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?

DENTSPLY SIRONA (XRAY) is set to report Q2 2025 earnings on August 7th, with consensus estimates at $851.6 million in revenue and $0.29 EPS. The company navigates a complex environment, balancing strong global performance in its Imaging segment and stable SureSmile growth with persistent headwinds from the Byte aligner suspension, which is expected to negatively impact organic sales by approximately two percentage points. Additionally, U.S. orthodontics and CAD/CAM segments face challenges from soft discretionary spending and macroeconomic pressures, though operational cost initiatives are anticipated to stabilize gross margins. The Zacks model does not conclusively predict an earnings beat for XRAY, despite its Zacks Rank #2.

Analysis

DENTSPLY SIRONA (XRAY) is approaching its Q2 2025 earnings release with a bifurcated operational outlook, according to pre-earnings analysis. The company is experiencing positive momentum in its Imaging segment, driven by the relaunch of Orthophos SL and the new Primescan 2, which are expected to boost scanner volumes, particularly in Europe and APAC. Similarly, the SureSmile orthodontic business is projected to show stable global growth. However, these strengths are significantly counteracted by persistent headwinds. The suspension of Byte aligner sales is a primary concern, anticipated to create a two-percentage-point drag on organic sales for the full year 2025. Furthermore, the U.S. market remains a weak spot, with soft discretionary spending and competitive pressures challenging the orthodontics segment, while cautious capital spending by dental practices has subdued demand for Connected Technology Solutions (CAD/CAM) despite new product introductions. While the company's cost-saving initiatives are expected to gradually stabilize gross margins, the Zacks model does not forecast an earnings beat, reflected by a negative Earnings ESP of -0.99%, creating a cautious backdrop for the upcoming report which has consensus estimates of $851.6 million in revenue and $0.29 EPS.

Key Decisions for Investors

• Given the significant headwinds from the Byte aligner suspension and U.S. market softness offsetting strength in the Imaging segment, investors should maintain a cautious stance, as the negative Earnings ESP of -0.99% suggests a notable risk of an earnings miss.
• Key metrics to scrutinize in the Q2 report will be the precise impact of the Byte suspension on organic sales, the performance of U.S. orthodontics and CAD/CAM units, and any sequential improvement in gross margins which would validate progress on cost-saving initiatives.
• Forward-looking guidance will be paramount; investors should focus on management's updated outlook on full-year growth, the path to margin stabilization, and any strategic shifts to counter competitive pressures and soft discretionary spending in North America.